Kiniksa Pharmaceuticals International, plc
KNSA
Kedudukan dalam Saham
#2965
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Harga Saham
$80.60
Modal Pasaran
$6.29B
Perubahan (1 hari)
1.41%
Perubahan (1 tahun)
106.72%
Negara
GB
Perdagangan Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
Nisbah P/B bagi Kiniksa Pharmaceuticals International, plc (KNSA)
Nisbah P/B pada October 2026 TTM: 9.35
Menurut laporan kewangan dan harga saham terkini Kiniksa Pharmaceuticals International, plc, nisbah P/B semasa (TTM) ialah 9.35. Pada akhir 2023, nisbah P/B syarikat ialah 2.80.
Sejarah nisbah P/B untuk Kiniksa Pharmaceuticals International, plc dari 2016 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 9.35 | 190.37% |
| 2024 | 3.22 | 15.07% |
| 2023 | 2.80 | -232.57% |
| 2022 | -2.11 | 76.75% |
| 2021 | -1.20 | -43.41% |
| 2020 | -2.11 | 25.79% |
| 2019 | -1.68 | -60.72% |
| 2018 | -4.27 | -39.36% |
| 2017 | -7.05 | -71.32% |
| 2016 | -24.57 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 3.8424 | -58.90% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 17.3539 | 85.61% |
US
|
